Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Teva Pharmaceutical Industries (TEVA) Share Price

News headlines about Teva Pharmaceutical Industries (NYSE:TEVA) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.9626048353246 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern’s rankings:

Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.32 during trading on Monday, reaching $21.02. 20,758,579 shares of the company were exchanged, compared to its average volume of 27,110,000. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $37.94. The stock has a market cap of $20,960.00, a price-to-earnings ratio of -3.58, a price-to-earnings-growth ratio of 1.48 and a beta of 0.54. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, November 2nd. The company reported $0.95 EPS for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.08). Teva Pharmaceutical Industries had a negative net margin of 24.35% and a positive return on equity of 15.70%. equities research analysts anticipate that Teva Pharmaceutical Industries will post 3.74 earnings per share for the current fiscal year.

Several equities analysts have commented on TEVA shares. ValuEngine raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Tuesday, December 5th. Evercore ISI set a $38.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Cantor Fitzgerald set a $17.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Thursday, October 26th. Morgan Stanley set a $15.00 target price on shares of Teva Pharmaceutical Industries and gave the stock an “underweight” rating in a research report on Thursday, October 5th. Finally, Mizuho reaffirmed a “hold” rating and issued a $15.00 price target on shares of Teva Pharmaceutical Industries in a report on Monday, October 30th. Eight investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $21.32.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Insider Buying and Selling by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit